Mandeep Kaur Marway
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mandeep Kaur Marway has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Boyang Zhang
School of Information and Communication Engineering, North University of China, Taiyuan 030051, China
3 shared publications - Ryan Gavin Wylie
McMaster University
2 shared publications Alistar J Ingram
Division of Nephrology, McMaster University at Hamilton, Ontario, Canada
1 shared publicationAnthony D. D’aNgelo
Department of Chemistry and Chemical Biology, McMaster University, Hamilton, Canada
1 shared publicationBo Gao
Division of Nephrology, McMaster University at Hamilton, Ontario, Canada
1 shared publicationChao Lu
Department of Medicine, Division of Nephrology, McMaster University and St. Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada
1 shared publication
Latest Publications
- 3 February 2026
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 16 (10) , 1-19
Beyond the dose: a clearance-enabled in vitro platform for evaluating local therapies
Inclusion of physiologically relevant clearance mechanisms into organ-on-a-chip models is essential to reproduce tissue exposure and predict therapeutic efficacy, especially for local therapies and drug delivery applications that are already common in the clinic for ocular and cancer treatments. There remains a need for clearance-enabled organ-on-a-chips amenable to high throughput screening, especially with the emerging trend to expedite formulation and drug delivery vehicle (DDV) design with machine learning. To address this gap, we developed a microfluidic platform that incorporates continuous, pressure-driven clearance through interconnected microchannels and three-dimensional (3D) systems, enabling translational evaluation of local therapies and DDVs, such as injectable hydrogels, that aim to reduce systemic toxicity and enhance efficacy by prolonging drug residence at disease sites. In this study, fluorescent 4 and 65 kDa dextrans were used to confirm that pressure gradients across the platform promote efficient clearance versus passive diffusion. The pressure gradients were then applied to breast cancer spheroids co-cultured with macrophages in a fibrin hydrogel to evaluate the therapeutic efficacy of an interferon gamma (IFN-γ)-releasing agarose hydrogel in combination with anti-human epidermal growth factor receptor 2 (anti-HER2). Fluorescent imaging of spheroid area revealed increased cancer cell viability, lower drug efficacy, when continuous clearance was present, highlighting the impact of drug clearance. This study establishes the clearance-enabled microfluidic platform as a translationally relevant in vitro model for evaluating local therapies under continuous clearance, thereby bridging the gap between traditional static platforms and in vivo models for evaluating local pharmacokinetics and pharmacodynamics. Graphical abstract The IFlowPlate-T models tunable clearance in 3D. IFN-γ and anti-HER2 efficacy decreased under pressure-driven flow, emphasizing clearance modeling.
- 3 February 2026
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 16 (10) , 1-19
Beyond the dose: a clearance-enabled in vitro platform for evaluating local therapies
Inclusion of physiologically relevant clearance mechanisms into organ-on-a-chip models is essential to reproduce tissue exposure and predict therapeutic efficacy, especially for local therapies and drug delivery applications that are already common in the clinic for ocular and cancer treatments. There remains a need for clearance-enabled organ-on-a-chips amenable to high throughput screening, especially with the emerging trend to expedite formulation and drug delivery vehicle (DDV) design with machine learning. To address this gap, we developed a microfluidic platform that incorporates continuous, pressure-driven clearance through interconnected microchannels and three-dimensional (3D) systems, enabling translational evaluation of local therapies and DDVs, such as injectable hydrogels, that aim to reduce systemic toxicity and enhance efficacy by prolonging drug residence at disease sites. In this study, fluorescent 4 and 65 kDa dextrans were used to confirm that pressure gradients across the platform promote efficient clearance versus passive diffusion. The pressure gradients were then applied to breast cancer spheroids co-cultured with macrophages in a fibrin hydrogel to evaluate the therapeutic efficacy of an interferon gamma (IFN-γ)-releasing agarose hydrogel in combination with anti-human epidermal growth factor receptor 2 (anti-HER2). Fluorescent imaging of spheroid area revealed increased cancer cell viability, lower drug efficacy, when continuous clearance was present, highlighting the impact of drug clearance. This study establishes the clearance-enabled microfluidic platform as a translationally relevant in vitro model for evaluating local therapies under continuous clearance, thereby bridging the gap between traditional static platforms and in vivo models for evaluating local pharmacokinetics and pharmacodynamics. Graphical abstract The IFlowPlate-T models tunable clearance in 3D. IFN-γ and anti-HER2 efficacy decreased under pressure-driven flow, emphasizing clearance modeling.
- 17 July 2025
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 11 (8) , 5038-5050
Crossing Barriers: In Vitro Cancer Model for Studying Monocyte Migration across Endothelial Barriers
Monocytes originate in the bone marrow and make up 2-10% of all white blood cells, circulating in the blood to damaged tissue and disease sites, where they differentiate into macrophages or dendritic cells. In solid tumors such as glioblastoma, monocytes recruited from the blood to the tumor site differentiate into tumor-associated macrophages (TAMs), which play a key role in tumor progression and metastasis. The endothelial vessel wall plays a significant role in the migration, activation, and polarization of these monocytes. Therefore, it is crucial to incorporate an endothelial cell (EC) barrier within an in vitro cancer model for elucidating transendothelial migration of monocytes along with high-throughput screening capabilities. The IFlowPlate is a high-throughput organ-on-a-chip device created on a 384-well plate modified by creating 128 tissue compartments created by connecting three wells with a single channel to model interstitial flow. Due to its simple design, it can be easily modified to model any tissue type. To study the effects of the EC barrier on tumor-promoted monocyte migration, cancer spheroids were embedded within a fibrin hydrogel with an EC barrier on the hydrogel surface to mimic the vessel wall. THP-1 monocyte migration was observed in the presence of patient-derived glioblastoma cancer spheroids and interstitial flow, and the presence of the human umbilical vein endothelial cell (HUVEC) barrier slowed and reduced monocyte migration compared with controls without EC barriers. Inflammatory cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-6 (IL-6), interleukin-10 (IL-10), and interleukin-1β (IL-1β) secretion levels increased, while tumor necrosis factor α (TNF-α) and interleukin-12p40 (IL-12p40) levels decreased and monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) levels remained unchanged in the presence of the EC barrier and spheroids, confirming the importance of the EC barrier for monocyte activation and migration. The EC barrier plays a crucial role in promoting and controlling monocyte migration in vivo. The IFlowPlate with a functional EC barrier can be used to model monocyte migration in vitro to study the role of monocytes in cancer prognosis.
- 17 July 2025
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 11 (8) , 5038-5050
Crossing Barriers: In Vitro Cancer Model for Studying Monocyte Migration across Endothelial Barriers
Monocytes originate in the bone marrow and make up 2-10% of all white blood cells, circulating in the blood to damaged tissue and disease sites, where they differentiate into macrophages or dendritic cells. In solid tumors such as glioblastoma, monocytes recruited from the blood to the tumor site differentiate into tumor-associated macrophages (TAMs), which play a key role in tumor progression and metastasis. The endothelial vessel wall plays a significant role in the migration, activation, and polarization of these monocytes. Therefore, it is crucial to incorporate an endothelial cell (EC) barrier within an in vitro cancer model for elucidating transendothelial migration of monocytes along with high-throughput screening capabilities. The IFlowPlate is a high-throughput organ-on-a-chip device created on a 384-well plate modified by creating 128 tissue compartments created by connecting three wells with a single channel to model interstitial flow. Due to its simple design, it can be easily modified to model any tissue type. To study the effects of the EC barrier on tumor-promoted monocyte migration, cancer spheroids were embedded within a fibrin hydrogel with an EC barrier on the hydrogel surface to mimic the vessel wall. THP-1 monocyte migration was observed in the presence of patient-derived glioblastoma cancer spheroids and interstitial flow, and the presence of the human umbilical vein endothelial cell (HUVEC) barrier slowed and reduced monocyte migration compared with controls without EC barriers. Inflammatory cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-6 (IL-6), interleukin-10 (IL-10), and interleukin-1β (IL-1β) secretion levels increased, while tumor necrosis factor α (TNF-α) and interleukin-12p40 (IL-12p40) levels decreased and monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) levels remained unchanged in the presence of the EC barrier and spheroids, confirming the importance of the EC barrier for monocyte activation and migration. The EC barrier plays a crucial role in promoting and controlling monocyte migration in vivo. The IFlowPlate with a functional EC barrier can be used to model monocyte migration in vitro to study the role of monocytes in cancer prognosis.
- 12 July 2020
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 7 (7) , 2964-2972
From Model System to Therapy: Scalable Production of Perfusable Vascularized Liver Spheroids in “Open-Top“ 384-Well Plate
Vasculature is a key component of many biological tissues and helps to regulate a wide range of biological processes. Modeling vascular networks or the vascular interface in organ-on-a-chip systems is an essential aspect of this technology. In many organ-on-a-chip devices, however, the engineered vasculatures are usually designed to be encapsulated inside closed microfluidic channels, making it difficult to physically access or extract the tissues for downstream applications and analysis. One unexploited benefit of tissue extraction is the potential of vascularizing, perfusing, and maturing the tissue in well-controlled, organ-on-a-chip microenvironments and then subsequently extracting that product for in vivo therapeutic implantation. Moreover, for both modeling and therapeutic applications, the scalability of the tissue production process is important. Here we demonstrate the scalable production of perfusable and extractable vascularized tissues in an “open-top“ 384-well plate (referred to as IFlowPlate), showing that this system could be used to examine nanoparticle delivery to targeted tissues through the microvascular network and to model vascular angiogenesis. Furthermore, tissue spheroids, such as hepatic spheroids, can be vascularized in a scalable manner and then subsequently extracted for in vivo implantation. This simple multiple-well plate platform could not only improve the experimental throughputs of organ-on-a-chip systems but could potentially help expand the application of model systems to regenerative therapy.
- 12 July 2020
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 7 (7) , 2964-2972
From Model System to Therapy: Scalable Production of Perfusable Vascularized Liver Spheroids in “Open-Top“ 384-Well Plate
Vasculature is a key component of many biological tissues and helps to regulate a wide range of biological processes. Modeling vascular networks or the vascular interface in organ-on-a-chip systems is an essential aspect of this technology. In many organ-on-a-chip devices, however, the engineered vasculatures are usually designed to be encapsulated inside closed microfluidic channels, making it difficult to physically access or extract the tissues for downstream applications and analysis. One unexploited benefit of tissue extraction is the potential of vascularizing, perfusing, and maturing the tissue in well-controlled, organ-on-a-chip microenvironments and then subsequently extracting that product for in vivo therapeutic implantation. Moreover, for both modeling and therapeutic applications, the scalability of the tissue production process is important. Here we demonstrate the scalable production of perfusable and extractable vascularized tissues in an “open-top“ 384-well plate (referred to as IFlowPlate), showing that this system could be used to examine nanoparticle delivery to targeted tissues through the microvascular network and to model vascular angiogenesis. Furthermore, tissue spheroids, such as hepatic spheroids, can be vascularized in a scalable manner and then subsequently extracted for in vivo implantation. This simple multiple-well plate platform could not only improve the experimental throughputs of organ-on-a-chip systems but could potentially help expand the application of model systems to regenerative therapy.
- 5 February 2018
- Published by The Endocrine Society in Endocrinology
- Vol. 159 (3) , 1479-1495
Inhibition of SREBP With Fatostatin Does Not Attenuate Early Diabetic Nephropathy in Male Mice
Sterol regulatory element binding protein (SREBP) is an important potential mediator of kidney fibrosis, and is known to be upregulated in diabetic nephropathy. Here we evaluate the effectiveness of SREBP inhibition as treatment for diabetic nephropathy. Type 1 diabetes was induced in uninephrectomized male CD1 mice with streptozotocin. Mice were treated with the SREBP inhibitor fatostatin for 12 weeks. At endpoint, kidney function and pathology were assessed. Fatostatin inhibited the increase of both isoforms of SREBP (1 and 2) in diabetic kidneys. Treatment attenuated basement membrane thickening, but did not improve hyperfiltration, albuminuria or kidney fibrosis in diabetic mice. Surprisingly, treatment of non-diabetic mice with fatostatin led to hyperfiltration and increased glomerular volume to levels seen in diabetic mice. This was associated with increased renal inflammation and a trend to increased renal fibrosis. Both in vivo and in cultured renal proximal tubular epithelial cells, fatostatin increased expression of the pro-inflammatory cytokine monocyte chemoattracant protein-1 (MCP-1). Thus, SREBP inhibition with fatostatin is not only ineffective in preventing diabetic nephropathy, but it also leads to kidney injury in non-diabetic mice. Further research on the efficacy of other SREBP inhibitors, and the specific roles of SREBP-1 and -2, in the treatment and pathogenesis of diabetic nephropathy need to be evaluated.
- 5 February 2018
- Published by The Endocrine Society in Endocrinology
- Vol. 159 (3) , 1479-1495
Inhibition of SREBP With Fatostatin Does Not Attenuate Early Diabetic Nephropathy in Male Mice
Sterol regulatory element binding protein (SREBP) is an important potential mediator of kidney fibrosis, and is known to be upregulated in diabetic nephropathy. Here we evaluate the effectiveness of SREBP inhibition as treatment for diabetic nephropathy. Type 1 diabetes was induced in uninephrectomized male CD1 mice with streptozotocin. Mice were treated with the SREBP inhibitor fatostatin for 12 weeks. At endpoint, kidney function and pathology were assessed. Fatostatin inhibited the increase of both isoforms of SREBP (1 and 2) in diabetic kidneys. Treatment attenuated basement membrane thickening, but did not improve hyperfiltration, albuminuria or kidney fibrosis in diabetic mice. Surprisingly, treatment of non-diabetic mice with fatostatin led to hyperfiltration and increased glomerular volume to levels seen in diabetic mice. This was associated with increased renal inflammation and a trend to increased renal fibrosis. Both in vivo and in cultured renal proximal tubular epithelial cells, fatostatin increased expression of the pro-inflammatory cytokine monocyte chemoattracant protein-1 (MCP-1). Thus, SREBP inhibition with fatostatin is not only ineffective in preventing diabetic nephropathy, but it also leads to kidney injury in non-diabetic mice. Further research on the efficacy of other SREBP inhibitors, and the specific roles of SREBP-1 and -2, in the treatment and pathogenesis of diabetic nephropathy need to be evaluated.
- Open Access
- 2 February 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep41572
Endoplasmic reticulum stress inhibition attenuates hypertensive chronic kidney disease through reduction in proteinuria
Endoplasmic reticulum (ER) stress is implicated in chronic kidney disease (CKD) development in patients and in animal models. Here we show that ER stress inhibition through 4-phenylbutyric acid (4-PBA) administration decreases blood pressure, albuminuria, and tubular casts in an angiotensin II/deoxycorticosterone acetate/salt murine model of CKD. Lower albuminuria in 4-PBA-treated mice was associated with higher levels of cubilin protein in renal tissue membrane fractions. 4-PBA decreased renal interstitial fibrosis, renal CD3+ T-cell and macrophage infiltration, mRNA expression of TGFβ1, Wnt signaling molecules, and ER stress-induced pro-inflammatory genes. CHOP deficient mice that underwent this model of CKD developed hypertension comparable to wild type mice, but had less albuminuria and tubular casts. CHOP deficiency resulted in higher nephrin levels and decreased glomerulosclerosis compared to wild type mice; this effect was accompanied by lower macrophage infiltration and fibrosis. Our findings portray ER stress inhibition as a means to alleviate hypertensive CKD by preserving glomerular barrier integrity and tubular function. These results demonstrate ER stress modulation as a novel target for preserving renal function in hypertensive CKD.
- 2 February 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep41572
Open AccessEndoplasmic reticulum stress inhibition attenuates hypertensive chronic kidney disease through reduction in proteinuria
Endoplasmic reticulum (ER) stress is implicated in chronic kidney disease (CKD) development in patients and in animal models. Here we show that ER stress inhibition through 4-phenylbutyric acid (4-PBA) administration decreases blood pressure, albuminuria, and tubular casts in an angiotensin II/deoxycorticosterone acetate/salt murine model of CKD. Lower albuminuria in 4-PBA-treated mice was associated with higher levels of cubilin protein in renal tissue membrane fractions. 4-PBA decreased renal interstitial fibrosis, renal CD3+ T-cell and macrophage infiltration, mRNA expression of TGFβ1, Wnt signaling molecules, and ER stress-induced pro-inflammatory genes. CHOP deficient mice that underwent this model of CKD developed hypertension comparable to wild type mice, but had less albuminuria and tubular casts. CHOP deficiency resulted in higher nephrin levels and decreased glomerulosclerosis compared to wild type mice; this effect was accompanied by lower macrophage infiltration and fibrosis. Our findings portray ER stress inhibition as a means to alleviate hypertensive CKD by preserving glomerular barrier integrity and tubular function. These results demonstrate ER stress modulation as a novel target for preserving renal function in hypertensive CKD.